Abstract The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade. with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients with BRAF mutations. combinations of BRAF and MEK inhibitors demonstrated response rates and benefit comparable to those from immune checkpoint inhibitors. https://www.roneverhart.com/HP-Notebook-15-da0008ca-HD-LED-15-6-Touchscreen-Intel-Core-i5-8250U-1-6-GHz-8-GB-RAM-1-TB-SSD-HDMI-USB-Multi-format-S/